Table 3:

Mucociliary Clearance and Deposition Data

	Baseline	First Dose	4 weeks	Mean 4 week change
Placebo
Whole Lung
AveClr60 (%)	11.8 ± 11.2	10.2 ± 8.7	10.3 ± 8.3	−3.1 ± 5.5 (CI: −7.8 – 1.5)
AveClr90 (%)	13.9 ± 10.7	12.6 ± 9.8	13.3 ± 9.3	−2.3 ± 5.2 (CI: −6.7 – 2.0)
24-hr Clearance (%)	33.4 ± 6.8	35.4 ± 5.9	34.8 ± 14.1	0.6 ± 11.9 (CI: −9.4 – 10.6)
C/P ratio	1.83 ± 0.20	2.09 ± 0.14*	1.92 ± 0.25	0.12 ± 0.23 (CI: −0.07 – 0.30)
Central Lung
AveClr90 (%)	22.0 ± 15.4	17.8 ± 15.7	21.0 ± 14.5	−3.8 ± 9.3 (CI: −11.6 – 4.0)
Peripheral Lung
AveClr90 (%)	8.5 ± 10.4	8.9 ± 5.6	7.8 ± 5.8	−1.7 ± 8.9 (CI: −9.2 – 5.7)
Active Treatment
Whole Lung
AveClr60 (%)	7.5 ± 5.2	8.3 ± 5.2	9.9 ± 6.2	1.6 ± 4.1 (CI: −1.2 – 4.3)**
AveClr90 (%)	9.1 ± 5.1	10.5 ± 5.9	12.6 ± 6.4*	2.8 ± 3.2 (CI: 0.6 – 4.9)**
24-hr Clearance (%)	24.0 ± 8.8	38.6 ± 12.8*	25.0 ± 8.0	1.6 ± 6.1 (CI: −2.3 – 5.5)
C/P ratio	1.67 ± 0.32	1.87 ± 0.35*	1.66 ± 0.26	−0.01 ± 0.26 (CI: −0.18 – 0.15)
Central Lung
AveClr90 (%)	16.2 ± 13.6	16.8 ± 8.7	20.8 ± 9.2	2.6 ± 9.0 (CI: −3.5 – 8.6)
Peripheral Lung
AveClr90 (%)	6.1 ± 4.4	6.5 ± 4.8	7.3 ± 4.9	1.1 ± 4.7 (CI: −2.1 – 4.3)

Clearance and deposition values at each time point, and calculated mean differences between baseline and 4 week visit.

^*Significant difference (p < 0.05) from baseline via paired T-test.

^**Significant difference (p < 0.05) between groups via unpaired T-test.